Absence of this transporter in vivo sensitizes animals to taxanes, with Mrp7−/− mice exhibiting increased sensitivity compared to their wild-type counterparts following paclitaxel treatment [12], implying that increased MRP7 expression might be a biomarker for and regulator of treatment response in certain cancers. This evidence concerns the gene ABCC10 and cancer.